Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 28, 2025 02:00 ET | Source: F. Hoffmann-La Roche Ltd

Positive phase III results for Roche’s Gazyva/Gazyvaro in children and young adults with idiopathic nephrotic syndrome

Gazyva/Gazyvaro versus mycophenolate mofetil shows significantly more children and young adults achieved sustained complete remission at week 52 If approved, Gazyva/Gazyvaro could help children and...
October 27, 2025 08:00 ET | Source: Evaxion

Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record of strategic partnership dealsHer more than...
October 27, 2025 07:45 ET | Source: BioNTech SE

BioNTech veröffentlicht am 3. November 2025 Ergebnisse für das dritte Quartal 2025 und informiert über operativen Fortschritt

MAINZ, Deutschland, 27. Oktober 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird am Montag, den 3. November 2025, die Ergebnisse für das dritte Quartal 2025...
October 27, 2025 07:45 ET | Source: BioNTech SE

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

MAINZ, Germany, October 27, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2025 on Monday, November 3, 2025....
October 24, 2025 09:27 ET | Source: Spherix Global Insights

Evolving Treatment Landscape for Chronic Spontaneous Urticaria Highlights Significant Unmet Needs and Expanding Opportunities for Therapeutic Innovation

EXTON, PA, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Chronic spontaneous urticaria (CSU), marked by unpredictable and often debilitating flare patterns, continues to impose a significant burden on patients...
October 23, 2025 01:30 ET | Source: F. Hoffmann-La Roche Ltd

Changes to the Roche Enlarged Corporate Executive Committee

Basel, 23 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Nina Schwab-Hautzinger (1975) has been appointed Head of Group Communications and a member of the enlarged Corporate...
October 23, 2025 01:00 ET | Source: F. Hoffmann-La Roche Ltd

[Ad-hoc-Mitteilung gemäss Art. 53] Roche setzt starkes Wachstum in den ersten neun Monaten 2025 fort: Verkäufe steigen um 7% (CER) – Gewinnprognose für das Gesamtjahr erhöht

Basel, 23. Oktober 2025 Konzernverkäufe stiegen in den ersten neun Monaten um 7%1 zu konstanten Wechselkursen (CER; 2% in CHF) aufgrund hoher Nachfrage nach innovativen Medikamenten und...
October 23, 2025 01:00 ET | Source: F. Hoffmann-La Roche Ltd

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong sales growth momentum of 7% (CER) in the first nine months of 2025; full-year earnings outlook raised

Basel, 23 October 2025 Group sales grew by 7%1 at constant exchange rates (CER; 2% in CHF) in the first nine months, driven by high demand for our innovative medicines and...
October 22, 2025 10:33 ET | Source: Research and Markets

Esophageal Cancer Pipeline Research Report 2025: Key Prospects Lie in Advanced Drugs Like S-588410 (Phase III) and Telomelysin (Phase II)

Dublin, Oct. 22, 2025 (GLOBE NEWSWIRE) -- The "Esophageal Cancer - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering. The report provides a thorough analysis of the...
October 22, 2025 08:00 ET | Source: Cassava Sciences, Inc.

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for...